Compare Gilead Sciences, Inc. (GILD) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Gilead Sciences, Inc. trades at $135.46 (market cap $164.99B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.35. The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| GILD | XDTE | |
|---|---|---|
Market Cap | $164.99B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $44.76 |
52-Week Low | $110.56 | $36.00 |
Enterprise Value | $188.06B | — |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.
The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.
XDTE trades at $39.46, up 0.65% with bullish technical signals from moving averages. The ETF generates weekly dividend distributions but faces scrutiny over yield sustainability and NAV erosion despite S&P 500 highs. Recent coverage highlights structural concerns about whether distributions represent true income or return of capital.
The fund offers high weekly income but carries significant risks including potential capital erosion and tax inefficiency. While technical momentum appears positive, fundamental concerns about the covered call strategy's long-term viability warrant caution for income-focused investors seeking sustainable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
